08:51 AM EDT, 03/19/2024 (MT Newswires) -- Tourmaline Bio ( TRML ) reported a Q4 net loss Tuesday of $0.81 per diluted share.

Analysts polled by Capital IQ expected a loss of $0.77.

As expected, the company reported no revenue for the quarter ended Dec. 31.

The late-stage clinical biotechnology company, which went public in October, reported cash, cash equivalents, and investments totaling $203 million as of Dec. 31, 2023.

The company said it expects it has enough cash runway to sustain operations into 2027.